Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls

Brain, Behavior, and Immunity

Volumn 32, Issue , 2013, Pages 105-111

  Zhang, Xiang Yang ^a,b   Tang, Wei ^c   Xiu, Mei Hong ^b   Chen, Da Chun ^b   Yang, Fu De ^b   Tan, Yun Long ^b   Wang, Zhi Ren ^b   Zhang, Feixue ^c   Liu, Jiahong ^c   Liu, Linjing ^c   Chen, Yuanling ^c   Wen, Na ^c   Kosten, Thomas R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PEKING UNIVERSITY   (China)

^c Zhejiang Provincial Clinical Research Center for Mental Disorder   (China)

Author keywords

Cognition; Immune function; Interleukin 18; Psychopathology; Schizophrenia

Indexed keywords

INTERLEUKIN 18;

ADULT; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; DISEASE ASSOCIATION; FEMALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SHORT TERM MEMORY; SYMPTOM ASSESSMENT;

EID: 84891372052     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.03.001     Document Type: Article

References (76)

1. Alboni, S., Cervia, D., Sugama, S., Conti, B., 2010. Interleukin 18 in the CNS. J. Neuroinflamm. 7, 9.
2. Alboni, S., Montanari, C., Benatti, C., Blom, J.M., Simone, M.L., Brunello, N., Caggia, F., Guidotti, G., Marcondes, M.C., Sanchez-Alavez, M., Conti, B., Tascedda, F., 2011. Constitutive and LPS-regulated expression of interleukin-18 receptor beta variants in the mouse brain. Brain Behav. Immun. 25 (3), 483-493.
3. Allan, S.M., Rothwell, N.J., 2001. Cytokines and acute neurodegeneration. Nat. Rev. Neurosci. 2 (10), 734-744.
4. Anderson, G., Maes, M., 2013. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 5-19.
5. Anderson, G., Berk, M., Dodd, S., Bechter, K., Altamura, A.C., Dell'osso, B., Kanba, S., Monji, A., Fatemi, S.H., Buckley, P., Debnath, M., Das, U.N., Meyer, U., Müller, N., Kanchanatawan, B., Maes, M., 2013. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 1-4.
6. Barch, D.M., 2010. Pharmacological strategies for enhancing cognition in schizophrenia. Curr. Top Behav. Neurosci. 4, 43-96.
7. Baune, B.T., Ponath, G., Golledge, J., Varga, G., Arolt, V., Rothermundt, M., Berger, K., 2008. Association between IL-8 cytokine and cognitive performance in an elderly general population-the MEMO-study. Neurobiol. Aging 29 (6), 937-944.
8. Bossu, P., Ciaramella, A., Salani, F., Bizzoni, F., Varsi, E., Di Iulio, F., Giubilei, F., Gianni, W., Trequattrini, A., Moro, M.L., Bernardini, S., Caltagirone, C., Spalletta, G., 2008. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment. Brain Behav. Immun. 22 (4), 487-492.
9. Brown, A.S., Derkits, E.J., 2010. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167 (3), 261-280.
10. Buckley, P.E., Evans, D., 2006. First-episode schizophrenia a window of opportunity for optimizing care and outcomes. Postgrad. Med. 51 (Spec No), 5-19.
11. Cannella, B., Raine, C.S., 2004. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann. Neurol. 55 (1), 46-57.
12. Chandrasekar, B., Vemula, K., Surabhi, R.M., Li-Weber, M., Owen-Schaub, L.B., Jensen, L.E., Mummidi, S., 2004. Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J. Biol. Chem. 279 (19), 20221-20233.
13. Chen, S.F., Hsu, C.W., Huang, W.H., Wang, J.Y., 2008. Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. Br. J. Pharmacol. 155 (8), 1279-1296.
14. Condray, R., Yao, J.K., 2011. Cognition dopamine and bioactive lipids in schizophrenia. Front Biosci. (Schol Ed) 3, 298-330.
15. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (1), 46-56.
16. Das, S., Mishra, M.K., Ghosh, J., Basu, A., 2008. Japanese encephalitis virus infection induces IL-18 and IL-1beta in microglia and astrocytes: correlation with in vitro cytokine responsiveness of glial cells and subsequent neuronal death. J. Neuroimmunol. 195 (1-2), 60-72.
17. Deverman, B.E., Patterson, P.H., 2009. Cytokines and CNS development. Neuron 64 (1), 61-78.
18. Dickerson, F., Boronow, J.J., Stallings, C., Origoni, A.E., Cole, S.K., Yolken, R.H., 2004. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the repeatable battery for the assessment of neuropsychological status. Psychiatry Res. 129 (1), 45-53.
19. Dinarello, C.A., Fantuzzi, G., 2003. Interleukin-18 and host defense against infection. J. Infect. Dis. 187 (Suppl. 2), 370-384.
20. Felderhoff-Mueser, U., Schmidt, O.I., Oberholzer, A., Buhrer, C., Stahel, P.F., 2005. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci. 28 (9), 487-493.
21. Galletly, C., 2009. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berlin) 202 (1-3), 259-273.
22. Ganguli, R., Brar, J.S., Chengappa, K.N., Yang, Z.W., Nimgaonkar, V.L., Rabin, B.S., 1993. Autoimmunity in schizophrenia: a review of recent findings. Ann. Med. 25 (5), 489-496.
23. Gaulden, J., Reiter, J.F., 2008. Neur-ons and neur-offs: regulators of neural induction in vertebrate embryos and embryonic stem cells. Hum. Mol. Genet. 17 (R1), 60-66.
24. Goff, D.C., Hill, M., Barch, D., 2011. The treatment of cognitive impairment in schizophrenia. Pharmacol. Biochem. Behav. 99 (2), 245-253.
25. Harvey, P.D., 2009. When does cognitive decline occur in the period prior to the first episode of schizophrenia? Psychiatry (Edgmont) 6 (7), 12-14.
26. Harvey, P.D., Green, M.F., Keefe, R.S., Velligan, D.I., 2004. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J. Clin. Psychiatry 65 (3), 361-372.
27. Irani, F., Kalkstein, S., Moberg, E.A., Moberg, P.J., 2011. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of crosssectional and longitudinal studies. Schizophr. Bull. 37 (6), 1318-1326.
28. Jeon, G.S., Park, S.K., Park, S.W., Kim, D.W., Chung, C.K., Cho, S.S., 2008. Glial expression of interleukin-18 and its receptor after excitotoxic damage in the mouse hippocampus. Neurochem. Res. 33 (1), 179-184.
29. Jonakait, G.M., 2007. The effects of maternal inflammation on neuronal development: possible mechanisms. Int. J. Dev. Neurosci. 25 (7), 415-425.
30. Kanno, T., Nagata, T., Yamamoto, S., Okamura, H., Nishizaki, T., 2004. Interleukin-18 stimulates synaptically released glutamate and enhances postsynaptic AMPA receptor responses in the CA1 region of mouse hippocampal slices. Brain Res. 1012 (1-2), 190-193.
31. Keefe, R.S., 2008. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 7 (1), 22-28.
32. Keshavan, M.S., 1999. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J. Psychiatr. Res. 33 (6), 513-521.
33. Keshavan, M.S., Hogarty, G.E., 1999. Brain maturational processes and delayed onset in schizophrenia. Dev. Psychopathol. 11 (3), 525-543.
34. Kumar, R.A., Cann, C., Hall, J.E., Sudheer, P.S., Wilkes, A.R., 2007. Predictive value of IL-18 and SC5b-9 for neurocognitive dysfunction after cardiopulmonary bypass. Br. J. Anaesth. 98 (3), 317-322.
35. Lin, A., Kenis, G., Bignotti, S., Tura, G.J., De Jong, R., Bosmans, E., Pioli, R., Altamura, C., Scharpe, S., Maes, M., 1998. The inflammatory response system in treatmentresistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32 (1), 9-15.
36. Liu, J., Zhou, Y., Li, S., Li, Y., Song, X., Wang, J., Wang, L., Ying, B., 2011. Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA Cell Biol. 30 (11), 913-917.
37. Losy, J., Niezgoda, A., 2001. IL-18 in patients with multiple sclerosis. Acta Neurol. Scand. 104 (3), 171-173.
38. Lynch, M.A., 2002. Interleukin-1 beta exerts a myriad of effects in the brain and in particular in the hippocampus: analysis of some of these actions. Vitam. Horm. 64, 185-219.
39. Ma, N., Tan, L.W., Wang, Q., Li, Z.X., Li, L.J., 2007. Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms. Psychiatry Res. 150 (1), 61-69.
40. Maes, M., Meltzer, H.Y., Bosmans, E., 1994. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89 (5), 346-351.
41. Maes, M., Goossens, F., Scharpe, S., Calabrese, J., Desnyder, R., Meltzer, H.Y., 1995. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res. 58 (3), 217-225.
42. Malaguarnera, L., Motta, M., Di Rosa, M., Anzaldi, M., Malaguarnera, M., 2006. Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology 26 (4), 307-312.
43. Meyer, U., 2013. Developmental neuroinflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 20-34.
44. Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70 (7), 663-671.
45. Miller, B.J., Culpepper, N., Rapaport, M.H., Buckley, P., 2013. Prenatal inflammation and eurodevelopment in schizophrenia: a review of human studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 92-100.
46. Minichiello, L., 2009. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci. 10 (12), 850-860.
47. Mori, I., Hossain, M.J., Takeda, K., Okamura, H., Imai, Y., Kohsaka, S., Kimura, Y., 2001. Impaired microglial activation in the brain of IL-18-gene-disrupted mice after neurovirulent influenza a virus infection. Virology 287 (1), 163-170.
48. Muller, N., Riedel, M., Ackenheil, M., Schwarz, M.J., 1999. The role of immune function in schizophrenia: an overview. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl. 4), 62-68.
49. Muller, N., Myint, A.M., Schwarz, M.J., 2011. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr. Pharm. Des. 17 (2), 130-136.
50. Nakanishi, K., Yoshimoto, T., Tsutsui, H., Okamura, H., 2001. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19, 423-474.
51. Naudin, J., Capo, C., Giusano, B., Mege, J.L., Azorin, J.M., 1997. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr. Res. 26 (2-3), 227-233.
52. Ozturk, C., Ozge, A., Yalin, O.O., Yilmaz, I.A., Delialioglu, N., Yildiz, C., Tesdelen, B., Kudiaki, C., 2007. The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: correlation with cognitive and functional decline. Behav. Neurol. 18 (4), 207-215.
53. Palmer, B.W., Heaton, R.K., Paulsen, J.S., Kuck, J., Braff, D., Harris, M.J., Zisook, S., Jeste, D.V., 1997. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 11 (3), 437-446.
54. Palmer, B.W., Dawes, S.E., Heaton, R.K., 2009. What do we know about neuropsychological aspects of schizophrenia? Neuropsychol. Rev. 19 (3), 365-384.
55. Pickering, M., O'Connor, J.J., 2007. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog. Brain Res. 163, 339-354.
56. Poo, M.M., 2001. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2 (1), 24-32.
57. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E., 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63 (8), 801-808.
58. Prinz, M., Hanisch, U.K., 1999. Murine microglial cells produce and respond to interleukin-18. J. Neurochem. 72 (5), 2215-2218.
59. Rajji, T.K., Mulsant, B.H., 2008. Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr. Res. 102 (1-3), 122-140.
60. Randolph, C., Tierney, M.C., Mohr, E., Chase, T.N., 1998. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 20 (3), 310-319.
61. Reale, M., Vianale, G., Lotti, L.V., Mariani-Costantini, R., Perconti, S., Cristaudo, A., Leopold, K., Antonucci, A., Di Giampaolo, L., Iavicoli, I., Di Gioacchino, M., Boscolo, P., 2011. Effects of palladium nanoparticles on the cytokine release from peripheral blood mononuclear cells of palladium-sensitized women. J. Occup. Environ. Med. 53 (9), 1054-1060.
62. Schmidt, O.I., Morganti-Kossmann, M.C., Heyde, C.E., Perez, D., Yatsiv, I., Shohami, E., Ertel, W., Stahel, P.F., 2004. Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury. J. Neuroinflamm. 1 (1), 13.
63. Sharma, T., Antonova, L., 2003. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am. 26 (1), 25-40.
64. Shirts, B.H., Wood, J., Yolken, R.H., Nimgaonkar, V.L., 2008. Comprehensive evaluation of positional candidates in the IL-18 pathway reveals suggestive associations with schizophrenia and herpes virus seropositivity. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 147 (3), 343-350.
65. Smith, R.S., Maes, M., 1995. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses 45 (2), 135-141.
66. Sparkman, N.L., Buchanan, J.B., Heyen, J.R., Chen, J., Beverly, J.L., Johnson, R.W., 2006. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J. Neurosci. 26 (42), 10709-10716.
67. Tanaka, K.F., Shintani, F., Fujii, Y., Yagi, G., Asai, M., 2000. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res. 96 (1), 75-80.
68. Tong, X.M., Zheng, S.E., Bader, A., Yao, H.P., Wu, N.P., Altmeyer, P., Brockmeyer, N.H., Jin, J., 2008. Construction of expression vector of hTERT-hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT. Eur. J. Med. Res. 13 (1), 7-14.
69. Tyler, W.J., Perrett, S.P., Pozzo-Miller, L.D., 2002. The role of neurotrophins in neurotransmitter release. Neuroscientist 8 (6), 524-531.
70. Wheeler, R.D., Culhane, A.C., Hall, M.D., Pickering-Brown, S., Rothwell, N.J., Luheshi, G.N., 2000. Detection of the interleukin 18 family in rat brain by RT-PCR. Brain Res. Mol. Brain Res. 77 (2), 290-293.
71. Wheeler, R.D., Brough, D., Le Feuvre, R.A., Takeda, K., Iwakura, Y., Luheshi, G.N., Rothwell, N.J., 2003. Interleukin-18 induces expression and release of cytokines from murine glial cells: interactions with interleukin-1 beta. J. Neurochem. 85 (6), 1412-1420.
72. Xiu, M.H., Chen da, C., Wang, D., Zhang, K., Dong, A., Tang, W., Zhang, F., Liu, L.J., Liu, J.H., Liu, H.B., Yang, F.D., Kosten, T.R., Zhang, X.Y., 2012. Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology. J. Psychiatr Res. 46 (8), 1093-1098.
73. Yaffe, K., Lindquist, K., Penninx, B.W., Simonsick, E.M., Pahor, M., Kritchevsky, S., Launer, L., Kuller, L., Rubin, S., Harris, T., 2003. Inflammatorymarkers and cognition inwellfunctioning African-American and white elders. Neurology 61 (1), 76-80.
74. Yirmiya, R., Goshen, I., 2011. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25 (2), 181-213.
75. Zhang, X.Y., Zhou, D.F., Cao, L.Y., Zhang, P.Y., Wu, G.Y., Shen, Y.C., 2004. Changes in serum interleukin-2,-6, and-8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 65 (7), 940-947.
76. Zhang, B.H., Tan, Y.L., Zhang, W.F., Wang, Z.R., Yang, G.G., Shi, C., Zhang, X.Y., Zhou, D.F., 2009. Repeatable battery for the assessment of neuropsychological status (RBANS) as a screening test in Chinese: reliability and validity. Chin. Ment. Health J. 28, 865-869.